在外周性角膜炎的生物学因素
Daniel Clarke1, Lauren Sartor2, Vu Do3
1Department of Ophthalmology, Royal Hobart Hospital, Tasmania, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Seminars in arthritis and rheumatism
|September 30, 2023
概括
生物疗法,包括rituximab,显示治疗严重的周边性角膜炎 (PUK) 的希望. 虽然证据有限,但这些治疗方法为耐火病例提供了有效的选择,特别是与自身免疫性疾病有关的病例.
科学领域:
- 眼科医生 眼科 眼科
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 在过去的20年里,生物疗法在治疗眼部炎症方面变得至关重要.
- 周围性角膜炎 (PUK) 是一种严重的眼部疾病,通常与全身性风湿性疾病有关.
- 从历史上看,PUK存在严重的失明和死亡风险,但新的治疗方法正在出现.
研究的目的:
- 审查现有证据,以使用生物疗法管理周围性角膜炎 (PUK).
- 提供有关PUK生物药物的临床应用,包括剂量和不良反应的指导.
- 评估生物制剂在PUK耐火病例中的疗效.
主要方法:
- 在主要数据库中进行了全面的文献搜索:Medline,Embase和Cochrane系统评论数据库.
- 搜索的重点是确定详细介绍PUK患者用生物剂治疗的同行评审文章.
- 分析了病例报告和病例系列,以收集有关治疗结果和不良事件的数据.
主要成果:
- 目前在PUK中生物使用的总体证据基础有限.
- 然而,报告的病例表明,生物药物在治疗耐火PUK方面越来越有效.
- 利图西马布在PUK的治疗中表现出特别高的疗效,这种疗效是二次性至粒状的PUK,并具有多炎.
结论:
- 生物疗法对耐火性PUK患者来说是一个强大而有效的治疗选择.
- 需要进一步的研究来加强证据基础,但目前的数据支持它们的使用.
- 在PUK中使用生物制剂的临床指导方针正在出现,对诸如rituximab等药物的具体考虑.
更多相关视频
06:30Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
222
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
9.2K
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164